Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 5/20 | 0.53 |
| ▸ | CYP26A1 | O43174 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SUCNR1 | Q9BXA5 | 2/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.45 |
| ▸ | UTS2R | Q9UKP6 | 6/20 | 0.44 |
| ▸ | MMP3 | P08254 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | MMP8 | P22894 | 1/20 | 0.43 |
| ▸ | MMP12 | P39900 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5926495 | 0.88 | CTSA (0.50) | CTSACYP26A1SUCNR1SERPINE1UTS2R | |
| SCHEMBL5927213 | 0.84 | CTSA (0.52) | CTSACYP26A1CASP3SERPINE1 | |
| SCHEMBL5926657 | 0.84 | ERAP1 (0.48) | MEN1KMT2A | |
| SCHEMBL5926688 | 0.83 | CTSA (0.58) | CTSACYP26A1SUCNR1UTS2RMMP3 | |
| SCHEMBL5927087 | 0.81 | CYP26A1 (0.49) | CTSACYP26A1UTS2R | |
| SCHEMBL5926999 | 0.80 | CTSA (0.61) | CTSACYP26A1 | |
| SCHEMBL5926904 | 0.80 | CTSA (0.50) | CTSACYP26A1MEN1KMT2ASUCNR1 | |
| SCHEMBL5927203 | 0.79 | CHRM1 (0.48) | CTSACYP26A1 | |
| SCHEMBL5927580 | 0.77 | CTSA (0.43) | CTSACYP26A1SUCNR1CASP3 | |
| SCHEMBL5926649 | 0.77 | ACLY (0.53) | CTSA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TFPI, F9, F2 | CTSA 426/4885CYP26A1 526/4885MEN1 3448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.